Your search history is turned on.
Date: May 1, 2024 Jurisdictions: British Columbia, Ontario
PharmaThers Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine TORONTO, May 1, 2024 -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (Sairiyo), a company that...
Date: April 22, 2024 Jurisdictions: British Columbia, Ontario
_ FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Carmelo Marrelli, Chief Financial Officer of PharmaTher Holdings Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of PharmaTher Holdings Ltd. (the issuer) for the interim period ended Februar...
_ FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Fabio Chianelli, Chairman & Chief Executive Officer of PharmaTher Holdings Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of PharmaTher Holdings Ltd. (the issuer) for the interim period en...
PHARMATHER HOLDINGS LTD. INTERIM MANAGEMENTS DISCUSSION AND ANALYSIS QUARTERLY HIGHLIGHTS Three and Nine Months Ended February 29, 2024 (Expressed in Canadian Dollars) Dated: April 19, 2024 PharmaTher Holdings Ltd. Interim Managements Discussion and Analysis Quarterly Highlig...
457 Q3 2024 - PharmaTher February 29, 2024 V5.pdf PHARMATHER HOLDINGS LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED FEBRUARY 29, 2024 AND FEBRUARY 28, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Notice To Reader The accompanying unaudited condensed interim consolidated financial statements of PharmaTher Holdings Ltd. (the "Company")...
Date: April 18, 2024 Jurisdictions: British Columbia, Ontario
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine TORONTO, April 18, 2024 -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of a Complete Response Letter (CRL) for its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine that was accepte...
Date: April 16, 2024 Jurisdictions: British Columbia, Ontario
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine TORONTO, April 16, 2024 -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine that ...
Date: February 21, 2024 Jurisdictions: British Columbia, Ontario
PharmaThers Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia TORONTO, Feb. 21, 2024 -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (Sairiyo), a company that is forty-nine percent (49%) owned by PharmaTher a...
Date: February 12, 2024 Jurisdictions: British Columbia, Ontario
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine TORONTO, Feb. 12, 2024 -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine that was accepted by the U.S. Food and Drug Administration (t...
Date: January 26, 2024 Jurisdictions: British Columbia, Ontario
_ FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Carmelo Marrelli, Chief Financial Officer of PharmaTher Holdings Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of PharmaTher Holdings Ltd. (the issuer) for the interim period ended Novembe...